| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
T24824-1mg促销 |
≥98% | ￥600.00 ￥540.00 |
10 | - | - | - | - |
|
T24824-5mg促销 |
≥98% | ￥1880.00 ￥1690.00 |
7 | - | - | - | - |
|
T24824-10mg促销 |
≥98% | ￥3000.00 ￥2700.00 |
7 | - | - | - | - |
|
T24824-25mg促销 |
≥98% | ￥5250.00 ￥4720.00 |
2 | - | - | - | - |
|
T24824-50mg促销 |
≥98% | ￥8400.00 ￥7560.00 |
2 | - | - | - | - |
|
| 靶点： | Phosphodiesterase | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR. | ||||||||||||||||||||
| 参考文献： | 1. Artigou JY, et al. [Evaluation of a new cardiotonic agent on human isolated atrium]. Ann Cardiol Angeiol (Paris). 1993 Feb;42(2):79-82. 2. Barrett JA, et al. Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity. J Cardiovasc Pharmacol. 1990 Oct;16(4):537-45. |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京